Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) has been assigned a consensus recommendation of “Buy” from the twenty-three brokerages that are presently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, nine have assigned a hold recommendation, twelve have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $82.03.

ALNY has been the subject of several analyst reports. Cowen and Company reiterated a “buy” rating and issued a $100.00 target price on shares of Alnylam Pharmaceuticals in a report on Tuesday, July 11th. Vetr downgraded shares of Alnylam Pharmaceuticals from a “strong-buy” rating to a “buy” rating and set a $71.50 target price for the company. in a report on Monday, May 15th. Piper Jaffray Companies set a $118.00 target price on shares of Alnylam Pharmaceuticals and gave the company a “buy” rating in a report on Monday, May 15th. Credit Suisse Group increased their target price on shares of Alnylam Pharmaceuticals from $90.00 to $96.00 and gave the company an “outperform” rating in a report on Tuesday, June 27th. Finally, Chardan Capital lowered their target price on shares of Alnylam Pharmaceuticals from $110.00 to $95.00 and set a “buy” rating for the company in a report on Monday, May 15th.

In other Alnylam Pharmaceuticals news, major shareholder Sanofi acquired 297,501 shares of the stock in a transaction dated Wednesday, May 31st. The stock was purchased at an average cost of $71.87 per share, for a total transaction of $21,381,396.87. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, VP Michael Mason sold 9,375 shares of the business’s stock in a transaction that occurred on Tuesday, May 16th. The stock was sold at an average price of $70.00, for a total transaction of $656,250.00. Following the completion of the sale, the vice president now owns 5,625 shares of the company’s stock, valued at $393,750. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 64,125 shares of company stock valued at $4,325,000. Company insiders own 4.30% of the company’s stock.

Several hedge funds and other institutional investors have recently modified their holdings of the company. FMR LLC increased its position in shares of Alnylam Pharmaceuticals by 0.3% in the first quarter. FMR LLC now owns 12,907,883 shares of the biopharmaceutical company’s stock valued at $661,530,000 after buying an additional 35,803 shares during the last quarter. Wellington Management Group LLP increased its position in shares of Alnylam Pharmaceuticals by 0.3% in the first quarter. Wellington Management Group LLP now owns 12,041,179 shares of the biopharmaceutical company’s stock valued at $617,111,000 after buying an additional 31,208 shares during the last quarter. Vanguard Group Inc. increased its position in shares of Alnylam Pharmaceuticals by 3.7% in the first quarter. Vanguard Group Inc. now owns 5,660,213 shares of the biopharmaceutical company’s stock valued at $290,086,000 after buying an additional 200,890 shares during the last quarter. BlackRock Inc. increased its position in shares of Alnylam Pharmaceuticals by 34,755.2% in the first quarter. BlackRock Inc. now owns 4,746,234 shares of the biopharmaceutical company’s stock valued at $243,242,000 after buying an additional 4,732,617 shares during the last quarter. Finally, Baillie Gifford & Co. increased its position in shares of Alnylam Pharmaceuticals by 0.5% in the first quarter. Baillie Gifford & Co. now owns 3,334,511 shares of the biopharmaceutical company’s stock valued at $170,894,000 after buying an additional 16,489 shares during the last quarter. 88.96% of the stock is currently owned by institutional investors.

Shares of Alnylam Pharmaceuticals (NASDAQ ALNY) traded down 1.80% during midday trading on Tuesday, reaching $81.44. 732,039 shares of the company’s stock traded hands. Alnylam Pharmaceuticals has a 52-week low of $31.38 and a 52-week high of $86.92. The firm’s market cap is $7.02 billion. The company has a 50 day moving average of $81.11 and a 200 day moving average of $60.45.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its earnings results on Friday, May 5th. The biopharmaceutical company reported ($1.25) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.22) by $0.03. The firm had revenue of $19 million during the quarter, compared to analysts’ expectations of $22.91 million. Alnylam Pharmaceuticals had a negative net margin of 705.11% and a negative return on equity of 42.90%. The business’s revenue for the quarter was up 160.3% on a year-over-year basis. During the same quarter in the prior year, the company earned ($1.21) EPS. On average, equities analysts predict that Alnylam Pharmaceuticals will post ($5.19) EPS for the current fiscal year.

WARNING: This story was first posted by American Banking News and is the sole property of of American Banking News. If you are viewing this story on another site, it was illegally copied and reposted in violation of U.S. and international copyright laws. The correct version of this story can be viewed at https://www.americanbankingnews.com/2017/08/08/alnylam-pharmaceuticals-inc-nasdaqalny-given-consensus-recommendation-of-buy-by-analysts.html.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).

Analyst Recommendations for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.